Encouraging results for cancer patients (cancer renal carcinoma)
Hi everybody,
I apologize for crossposting but I believe it is worthwhile.
Some exciting news has just been published today about an
antiangiogenic compound for cancer patients. Aeterna Laboratories, a
Canadian Biotech, released its phase III clinical trial results on
renal carcinoma. For a specific subgroup of patients, their product,
the Neovastat, increased the median survival time by 109% for patients
suffering of clear cell renal carcinoma with 1 metastasis in the lung.
These patients more than doubled their life expectancy from 12.6
months for the placebo group to 26.3% for the Neovastat group.
This subpopulation represents some of the "healthier" patients in this
study. It seems to confirm the paradigm that the earlier a patient is
treated with anti-angiogenic compounds, the better his or her chances
for a positive outcome.
Angiogenesis control has been confirmed again to be a promising
strategy to fight cancer. There is one dietary supplement on the
market with a similar mechanism of action, it's called CarTCell.
Best regards
Bill
|